Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced Friday morning that two Phase 3 studies evaluating dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis met their primary endpoints.
from RTT - Before the Bell http://ift.tt/1qjmHRz
via IFTTT
No comments:
Post a Comment